1542P First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

M Sebastian,M Reck,R.N Fischer,D.C.C Christoph,C Bernhardt,E Von Der Heyde,A Nusch,P Ludwig,A Hipper,J Hanselmann,T Medinger,A Binninger,M Jänicke,P Christopoulos,C Elender,A Bethge,B Seese,T.C Gauler,C Waller

doi:10.1016/j.annonc.2022.07.1636

Abstract

Treatment options for patients with small cell lung cancer (SCLC) have substantially improved with the approval of the first two checkpoint inhibitors (CPI), atezolizumab (2019) and durvalumab (2020), for stage IV SCLC. How are patients with SCLC treated outside of clinical trials and how do these new treatments change the outcome in routine care in Germany?

Full Text